The Ultimate Guide to Aripiprazole Toxicity: Symptoms, Treatment, and Prevention

Epidemiology of Aripiprazole Toxicity

Case Studies of Aripiprazole toxicity

Pediatric Exposures to Aripiprazole Toxicity:

• A case series reported on five pediatric cases, with toxicity mainly observed in younger patients. Clinical effects included marked lethargy and gastrointestinal upset. Adolescents tended to experience fewer and milder symptoms (Lofton & Klein-Schwartz, 2005).

• In one specific case, a 2-year-old experienced significant lethargy and tremor after ingesting 10 mg of aripiprazole, with symptoms persisting for over 72 hours (Melhem et al., 2009).

Aripiprazole Toxicity in Adolescents and Adults:

• A retrospective study reviewing 286 cases reported to poison control centers found that acute aripiprazole poisonings most commonly resulted in sedation, tachycardia, nausea, and dystonic reactions. Symptoms were more frequent with doses above 90 mg, although pediatric patients could be affected at lower doses (Young et al., 2009).

• A 14-year-old boy developed prolonged QRS widening without dysrhythmias after ingesting 100 mg of aripiprazole, highlighting potential cardiac risks (Mazer-Amirshahi et al., 2018).

Aripiprazole Toxicity in the General Population:

• Analysis of 280 human exposures reported to Texas poison control centers showed that 35% were isolated exposures while 65% involved multiple substances. Neurological, cardiovascular, and gastrointestinal symptoms were the most commonly reported adverse effects. Younger children (<6 years) were more likely to experience unintentional exposures (Forrester, 2006).

Pharmacokinetics of Aripiprazole:

Absorption of Aripiprazole:

Aripiprazole is well-absorbed following oral administration, with an absolute oral bioavailability of approximately 87%. It is not significantly affected by food, although high-fat meals might delay the rate of absorption (Mallikaarjun et al., 2004).

Aripiprazole Peak Concentration:

Aripiprazole reaches peak plasma concentrations within 3 to 5 hours after oral administration, consistent across different dosages, indicating a predictable pharmacokinetic profile (DeLeon et al., 2004).

Pharmacokinetic Studies of Aripiprazole:

• Study 1: Evaluated multiple oral dosing in healthy volunteers and found that aripiprazole displayed linear pharmacokinetics over the dose range of 5 to 30 mg per day. Peak concentrations were reached within approximately 3 hours (Mallikaarjun et al., 2004).

• Study 2: In a study of different aripiprazole formulations, including an orally disintegrating tablet, peak concentrations for all formulations were reached within 3 hours (Kim et al., 2015).

Metabolism and Half-Life of Aripiprazole

Metabolism:

Aripiprazole undergoes extensive hepatic metabolism, primarily via the cytochrome P450 enzymes CYP3A4 and CYP2D6. It is converted into its active metabolite, dehydro-aripiprazole, contributing to its therapeutic effects. The pharmacological activity of dehydro-aripiprazole is similar to that of the parent compound, with an affinity for dopamine D2 receptors (DeLeon et al., 2004).

Half-Life:

Aripiprazole has a relatively long elimination half-life, which supports once-daily dosing.

• The mean elimination half-life of aripiprazole ranges from approximately 47 to 68 hours, allowing for stable plasma concentrations with once-daily administration (Mallikaarjun et al., 2004).

• Dehydro-aripiprazole, the primary active metabolite, also has a long half-life, contributing to the overall duration of action.

Mechanism of Action of Aripiprazole

Neurotransmission balance and mood treatment

Aripiprazole's unique mechanism involves partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at serotonin 5-HT2A receptors. This combination of receptor activities helps balance dopaminergic and serotonergic neurotransmission, which is crucial for its antipsychotic effects (Mamo et al., 2007).

Partial Agonist: At D2 and 5-HT1A receptors, aripiprazole acts as a partial agonist, providing therapeutic benefits without complete receptor blockade, reducing the risk of extrapyramidal symptoms.

Antagonist: At 5-HT2A receptors, aripiprazole acts as an antagonist, contributing to its efficacy in treating mood and psychotic disorders.

Excretion of Aripiprazole

Aripiprazole is primarily eliminated from the body through hepatic metabolism. The main pathways involve the cytochrome P450 enzymes, specifically CYP3A4 and CYP2D6. Less than 1% of the administered dose is excreted unchanged in the urine (Sheehan et al., 2010).

Metabolism: Aripiprazole is metabolized to its active metabolite, dehydro-aripiprazole, which also contributes to its therapeutic effects. The metabolites are primarily excreted in feces (approximately 60%) and to a lesser extent in urine (about 40%) (Sheehan et al., 2010).

Bioavailability of Aripiprazole:

Aripiprazole has a high oral bioavailability, with approximately 87% of the dose being absorbed when administered orally (DeLeon et al., 2004).

Bioavailability Studies of Aripiprazole:

• Oral Tablets: A study comparing aripiprazole orally disintegrating tablets to conventional tablets found them to be bioequivalent, with no significant differences in absorption and overall bioavailability (Wu, 2006).

• Long-Acting Formulations: For intramuscular injections, such as aripiprazole lauroxil, bioavailability studies have shown that plasma concentrations reach steady levels over time, with a broad peak and prolonged exposure due to the drug's slow dissolution and elimination (Turncliff et al., 2014).

Mechanisms of Toxicity of Aripiprazole

Mechanisms of Aripiprazole Toxicity: Dopamine and Serotonin Modulation, Cardiac, and CNS Effects

Aripiprazole has a distinct pharmacological profile that contributes to its mechanisms of toxicity.

Dopamine and Serotonin Receptor Modulation:

• Partial Agonism at D2 Receptors: Partial agonism at D2 receptors means aripiprazole can both stimulate and inhibit dopaminergic activity depending on the existing dopamine levels, resulting in symptoms like extreme lethargy and tremor (Mamo et al., 2007).

• Serotonin Receptor Effects: Antagonism at 5-HT2A receptors and partial agonism at 5-HT1A receptors can affect mood regulation and cardiovascular function, leading to side effects such as hypotension, bradycardia, and sedation in overdose situations (Keck Jr. & McElroy, 2003).

Cardiac Toxicity:

• QRS Prolongation: Cases have been reported where overdose led to QRS prolongation without dysrhythmias, suggesting aripiprazole's potential to affect cardiac conduction in high doses (Mazer-Amirshahi et al., 2018).

• Atrial Fibrillation: Reports of atrial fibrillation occurring in patients with predisposing risk factors when aripiprazole is administered (D'Urso et al., 2018).

Central Nervous System Effects:

• Prolonged Sedation: Overdose cases, especially in pediatric patients, have shown prolonged periods of lethargy and sedation lasting up to 72 hours (Melhem et al., 2009).

• Neurological Symptoms: Symptoms such as tremors, ataxia, and Parkinsonian gait have been reported in severe toxicity cases (Lofton & Klein-Schwartz, 2005).

Toxic Dose of Aripiprazole

The lowest dose associated with any toxicity in children less than 12 years of age was 15 mg (0.6 mg/kg). For patients 12 years and older, doses exceeding five times the initial adult dose (i.e., aripiprazole 50 mg) require emergency department evaluation.

Pediatric Patients:

• Low-Dose Toxicity: A 2-year-old girl exhibited significant lethargy, tremor, and tachycardia after ingesting 10 mg of aripiprazole. Her measured drug level was 160 ng/mL, approximately 34 hours post-ingestion (Melhem et al., 2009).

• Moderate-Dose Toxicity: A 6-year-old experienced lethargy, drooling, and flaccid facial muscles after therapeutic doses. A 2-year-old who ingested 40 mg experienced vomiting and significant lethargy lasting approximately 30 hours (Lofton & Klein-Schwartz, 2005).

Adolescents and Adults:

• Higher-Dose Toxicity: Two adolescents remained asymptomatic despite 120 mg and 300 mg, respectively. However, a third of adolescents experienced transient lethargy with an unknown dose (Lofton & Klein-Schwartz, 2005).

• Adults: Symptoms such as somnolence, tachycardia, nausea, vomiting, and dystonic reactions at doses as low as 25 mg. Doses above 90 mg were more likely to cause symptoms (Young et al., 2009).

• Massive Overdose: A 27-year-old woman ingested 330 mg in a suicide attempt, resulting in mild sedation but no severe clinical effects (Carstairs & Williams, 2005).

• Severe Cardiac Effects: A 14-year-old boy ingested 100 mg and developed prolonged QRS widening without dysrhythmias, which persisted for eight days despite aggressive treatment (Mazer-Amirshahi et al., 2018).

Clinical Presentation of Aripiprazole Toxicity Based on Severity

Mild Aripiprazole Toxicity:

• Symptoms: The most commonly reported symptoms include drowsiness and lethargy.

• Study Evidence: A retrospective study found that 55% of patients exhibited symptoms, with somnolence reported in 56% of cases (Young et al., 2009).

Moderate Aripiprazole Toxicity:

• Symptoms: Higher doses are associated with somnolence and sedation.

• Study Evidence: Moderate toxicity was observed with symptoms including lethargy, drooling, and flaccid facial muscles, particularly in younger patients (Lofton & Klein-Schwartz, 2005).

Severe Aripiprazole Toxicity:

• Symptoms: Severe toxicity includes extreme lethargy, flat affect, tremors, ataxia, parkinsonian gait, vomiting, and coma.

• Study Evidence: Severe symptoms could include significant lethargy lasting several hours to days, tremors, and ataxia. Some cases exhibited Parkinsonian symptoms and required intensive care management (Lofton & Klein-Schwartz, 2005).

Management of Aripiprazole Toxicity based on severity:

Management of Mild to Moderate Aripiprazole Toxicity

Management of Mild Toxicity:

1. Observation at Home:

   • Children Under 12 Years: Children who have ingested less than 15 mg of aripiprazole and exhibit only mild symptoms can be observed at home with close monitoring and follow-up (Melhem et al., 2009).

   • Patients 12 Years and Older: Individuals who have ingested less than 50 mg of aripiprazole and exhibit mild symptoms can also be monitored at home (Young et al., 2009).

2. Symptomatic Treatment:

   • Hydration and Rest: Ensure the patient stays well-hydrated and rests.

   • Monitoring: Monitor vital signs to detect any changes that might indicate worsening toxicity.

Management of Moderate Toxicity:

1. Medical Evaluation:

   • Emergency Department Referral: Patients who have ingested higher doses or exhibit more pronounced symptoms should be referred to the emergency department for further evaluation (Young et al., 2009).

2. Symptomatic and Supportive Care:

   • Activated Charcoal: Consider administration if the patient presents within one hour of ingestion (Lofton & Klein-Schwartz, 2005).

   • Sedation Management: Ensure the patient is in a safe environment.

   • Hydration and Electrolyte Management: Provide IV fluids if necessary.

   • Antiemetics: Administer if the patient experiences nausea or vomiting.

3. Observation and Monitoring: Continuous monitoring for changes in mental status, cardiovascular signs, and development of more severe symptoms (Young et al., 2009).

Follow-Up Care:

1. Poison Control Center: Ensure follow-up with a poison control center.

2. Primary Care Follow-Up: Arrange follow-up with the patient’s primary care provider or psychiatrist.

Related Reading: For insights on managing poisoning cases adults , read our Comprehensive Guidelines for Managing Poisoning in Adults.

Management of Severe Aripiprazole Toxicity Based on US-Based Literature

Immediate Referral and Initial Care:

1. Emergency Department Referral: Patients presenting with severe symptoms should be immediately referred to an emergency department (Melhem et al., 2009).

2. Initial Assessment: Ensure the patient’s airway is open, monitor vital signs, and provide continuous cardiac monitoring (Mazer-Amirshahi et al., 2018).

Specific Interventions:

1. Activated Charcoal: Administer if the patient presents within one hour of ingestion (Lofton & Klein-Schwartz, 2005).

2. Sodium Bicarbonate: Administer in cases of QRS widening (Mazer-Amirshahi et al., 2018).

3. Intravenous Fluids: Administer to maintain hydration and correct electrolyte imbalances.

4. Symptomatic Treatment: Administer antiemetic medications and ensure a safe environment to manage extreme lethargy and sedation.

5. Monitoring and Supportive Care: ICU admission may require closer monitoring and advanced supportive care.

Follow-Up and Long-Term Care:

1. Observation Period: Due to the long half-life of aripiprazole and its active metabolite, monitor patients for an extended period.

2. Rehabilitation and Counseling: Provide psychological support and counseling.

3. Education and Prevention: Educate patients and caregivers about the risks of medication misuse and the importance of adhering to prescribed dosages.

Related Reading: For insights on managing poisoning cases in intensive care, read our Comprehensive Guide to Managing Poisoning in the Intensive Care Unit.

Antidote for Aripiprazole Toxicity

There is no specific antidote for aripiprazole poisoning. Management is primarily supportive and symptomatic (Young et al., 2009).

Observation Criteria for Aripiprazole Toxicity

Criteria for Home Observation:

1. Mild Symptoms:

   • Children Under 12 Years: Children who have ingested less than 15 mg of aripiprazole and exhibit only mild symptoms can be observed at home (Melhem et al., 2009).

   • Patients 12 Years and Older: Individuals who have ingested less than 50 mg of aripiprazole and exhibit mild symptoms can also be monitored at home (Young et al., 2009).

2. Follow-Up: Ensure follow-up contact with a poison control center.

Criteria for Emergency Department Observation:

1. Moderate to Severe Symptoms:

   • Significant Ingestion: Children who have ingested 15 mg or more and adults who have ingested 50 mg or more should be evaluated in the emergency department (Young et al., 2009).

   • Moderate Symptoms: Symptoms such as significant lethargy and cardiovascular instability warrant emergency evaluation (Lofton & Klein-Schwartz, 2005).

2. Observation Duration: Patients should be observed in a healthcare facility for 6-12 hours post-ingestion.

Extended Observation for Severe Cases:

1. Severe Symptoms: Patients exhibiting severe symptoms should be admitted for extended observation and intensive care (Lofton & Klein-Schwartz, 2005).

2. Cardiac Monitoring: Continuous cardiac monitoring is necessary due to the risk of arrhythmias, particularly QRS widening (Mazer-Amirshahi et al., 2018).

3. Neurological Monitoring: Regular assessments of neurological status are essential.

Prevention and Public Health Measures for Aripiprazole Toxicity

Safe Prescribing Practices for Aripiprazole:

1. Proper Dosing and Monitoring: Ensure that aripiprazole is prescribed at the correct dosage and regularly monitored (Swainston Harrison & Perry, 2004).

2. Education of Healthcare Providers: Provide training on the pharmacokinetics, potential side effects, and signs of toxicity of aripiprazole (Pigott et al., 2003).

Safe Storage and Handling of Aripiprazole:

1. Secure Storage: Educate patients and caregivers on the importance of storing medications securely (Lofton & Klein-Schwartz, 2005).

2. Proper Disposal: Provide guidelines on properly disposing of unused or expired medications.

Public Education and Awareness of Aripiprazole Toxicity:

1. Patient and Caregiver Education: Educate patients and their caregivers about the potential risks of aripiprazole (Melhem et al., 2009).

2. Public Awareness Campaigns: Implement public health campaigns to raise awareness about the safe use of psychotropic medications.

Poison Control and Emergency Preparedness for Aripiprazole Toxicity:

1. Poison Control Center Accessibility: Ensure that poison control centers are easily accessible.

2. Emergency Protocols: Develop and disseminate clear protocols for managing aripiprazole toxicity (Young et al., 2009).

Conclusion: Managing and Preventing Aripiprazole Toxicity:

Preventing aripiprazole toxicity involves a multi-faceted approach, including safe prescribing practices, secure storage and disposal, public education, and emergency preparedness. These measures can significantly reduce the risk of accidental ingestion and ensure prompt and effective toxicity management.

Read more:

Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management

Aripiprazole - Wikipedia